Drug Trial Radar · NCT03584516
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
155
Actual
Start
Jan 17, 2019
Primary completion
Nov 3, 2023
Study completion Nov 3, 2023
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Conditions
- Chronic Graft-versus-host Disease
Interventions
ItacitinibDrug
In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
PlaceboDrug
In Part 2, participants will receive matching placebo.
MethylprednisoloneDrug
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
PrednisoneDrug
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: up to Day 28
- Part 1 Expansion: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: until at least 30 days after the last dose of study treatment (up to 1103 days)
- Part 2: Response Rate at Month 6Time frame: Month 6
Locations
133 sites in 16 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center - Out Pt.
Tucson, Arizona
University of Arkansas For Medical Sciences - Winthrop P Rockefeller Cancer Institute
Little Rock, Arkansas
City of Hope National Medical Center
Duarte, California
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Augusta University - Medical College of Georgia
Augusta, Georgia
Rush University Medical Center
Chicago, Illinois
Illinois Cancer Specialists
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
Advocate Lutheran General Hospital - Oncology Specislists Sc
Park Ridge, Illinois
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Kansas Hospital Authority
Westwood, Kansas
Tulane University
New Orleans, Louisiana
University of Maryland - Greenebaum Cancer Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Spectrum Health
Grand Rapids, Michigan
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota
Saint Louis University Cancer Center
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
University of Rochester, James P. Wilmot Cancer Center
Rochester, New York
Stony Brook University Medical Center
Stony Brook, New York
Duke University Medical Center
Durham, North Carolina
Oncology Hematology Care, Inc
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania
Jefferson University Hospitals
Philadelphia, Pennsylvania
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Avera Cancer Institute
Sioux Falls, South Dakota
Tri Star Bone Marrow Transplant
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
St David'S South Austin Medical Center
Austin, Texas
Texas Oncology - Medical City Dallas
Dallas, Texas
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Ordensklinikum Linz Gmbh Elisabethinen
Linz, Austria
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.